Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Acetylshikonin is a naturally occurring **acetate ester** and a **hydroxy-1,4-naphthoquinone** derivative found in plants such as Lithospermum erythrorhizon and Arnebia species[2][5][8]. It is characterized as a **small molecule** with prominent **anti-cancer** and **anti-inflammatory** properties. Mechanistically, acetylshikonin acts as a **microtubule-targeting agent (MTA)** by inhibiting tubulin polymerization, causing G2/M phase cell cycle arrest and promoting apoptosis in various cancer cell lines (including hepatocellular carcinoma, renal cell carcinoma, and others)[3][6]. It also inhibits cytochrome P450 2J2 (CYP2J2) activity and induces nuclear translocation of forkhead box protein O3 (FOXO3)[6]. These properties collectively position acetylshikonin as a promising preclinical lead for research in oncology[3][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on acetylshikonin.